Inventor · disambiguated record
Eckard Weber
Also filed as: WEBER ECKARD
73 granted patents·36 pending applications·2,446 citations·filing 1983–2024
99Inventor score
Files withOREGON STATE30OREXIGEN THERAPEUTICS INC13CYTOVIA INC12NOVALAR PHARMACEUTICALS INC9NALPROPION PHARMACEUTICALS LLC5
Top patents by PatentIndex Score
109 records- 0199US4906779AN,N'-disubstituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1988·Granted Mar 6, 1990·115 cites·33 claims
- 0298US5514680AGlycine receptor antagonists and the use thereofOREGON STATE·Filed 1993·Granted May 7, 1996·206 cites·26 claims
- 0398US5262568ATri- and tetra-substituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1991·Granted Nov 16, 1993·91 cites·35 claims
- 0498US5093525AN,N'-disubstituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1990·Granted Mar 3, 1992·124 cites·51 claims
- 0597US8088786B2Layered pharmaceutical formulationsMCKINNEY ANTHONY·Filed 2007·Granted Jan 3, 2012·64 cites·6 claims
- 0697US5385946AMethod for treating hypertension with disubstituted granidine compoundsOREGON STATE·Filed 1993·Granted Jan 31, 1995·66 cites·26 claims
- 0796US9125868B2Methods for administering weight loss medicationsOREXIGEN THERAPEUTICS INC·Filed 2014·Granted Sep 8, 2015·40 cites·17 claims
- 0896US8722085B2Methods for administering weight loss medicationsMCKINNEY ANTHONY·Filed 2010·Granted May 13, 2014·45 cites·17 claims
- 0996US7569230B2Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereofNOVALAR PHARMACEUTICALS INC·Filed 2006·Granted Aug 4, 2009·32 cites·33 claims
- 1096US5336689ATri- and tetra-substituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1993·Granted Aug 9, 1994·90 cites·51 claims
- 1195US12048769B2Methods for administering weight loss medicationsNALPROPION PHARMACEUTICALS LLC·Filed 2020·Granted Jul 30, 2024·3 cites·20 claims
- 1295US7575757B2Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereofNOVALAR PHARMACEUTICALS INC·Filed 2005·Granted Aug 18, 2009·31 cites·27 claims
- 1395US7462626B2Compositions for affecting weight lossOREXIGEN THERAPEUTICS INC·Filed 2006·Granted Dec 9, 2008·42 cites·49 claims
- 1495US5312840ASubstituted guanidines having high binding to the sigma receptor and the use thereofOREGON STATE·Filed 1993·Granted May 17, 1994·51 cites·36 claims
- 1594US8318788B2Layered pharmaceutical formulationsMCKINNEY ANTHONY·Filed 2011·Granted Nov 27, 2012·25 cites·20 claims
- 1694US7375111B2Compositions for affecting weight lossOREXIGEN THERAPEUTICS INC·Filed 2004·Granted May 20, 2008·60 cites·8 claims
- 1794US6764678B2Local anesthetic methods and kitsNOVALAR PHARMACEUTICALS INC·Filed 2002·Granted Jul 20, 2004·59 cites·31 claims
- 1894US6759207B2Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereofCYTOVIA INC·Filed 2001·Granted Jul 6, 2004·46 cites·38 claims
- 1993US11278544B2Compositions for affecting weight lossNALPROPION PHARMACEUTICALS LLC·Filed 2019·Granted Mar 22, 2022·4 cites·7 claims
- 2093US7261889B2Local anesthetic methods and kitsNOVALAR PHARMACEUTICALS INC·Filed 2005·Granted Aug 28, 2007·21 cites·22 claims
- 2193US6355618B1Caspase inhibitors and the use thereofCYTOVIA INC·Filed 2000·Granted Mar 12, 2002·45 cites·42 claims
- 2292US6872390B2Local anesthetic methods and kitsNOVALAR PHARMACEUTICALS INC·Filed 2002·Granted Mar 29, 2005·35 cites·12 claims
- 2392US6432401B2Local anesthetic methods and kitsNOVALAR PHARMACEUTICALS INC·Filed 2001·Granted Aug 13, 2002·41 cites·8 claims
- 2492US6342611B1Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereofCYTOVIA INC·Filed 1998·Granted Jan 29, 2002·89 cites·41 claims
- 2592US4709094ASigma brain receptor ligands and their useOREGON STATE·Filed 1986·Granted Nov 24, 1987·82 cites·23 claims
- 2691US7229630B2Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereofNOVALAR PHARMACEUTICALS INC·Filed 2003·Granted Jun 12, 2007·34 cites·33 claims
- 2791US6613803B1Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereofEURO CELTIQUE SA·Filed 1999·Granted Sep 2, 2003·79 cites·38 claims
- 2890US6153591ADipeptide caspase inhibitors and the use thereofCYTOVIA INC·Filed 1999·Granted Nov 28, 2000·85 cites·49 claims
- 2990US5190976AN,N'-disubstituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1992·Granted Mar 2, 1993·107 cites·12 claims
- 3089US10307376B2Methods for administering weight loss medicationsNALPROPION PHARMACEUTICALS INC·Filed 2018·Granted Jun 4, 2019·5 cites·20 claims
- 3188US6566338B1Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell deathCYTOVIA INC·Filed 2000·Granted May 20, 2003·31 cites·19 claims
- 3288US5502255ASubstituted guanidines having high binding to the sigma receptor and the use thereofOREGON STATE·Filed 1993·Granted Mar 26, 1996·21 cites·6 claims
- 3387US6716818B2Caspase inhibitors and the use thereofCYTOVIA INC·Filed 2001·Granted Apr 6, 2004·22 cites·41 claims
- 3487US6596693B1Dipeptide apoptosis inhibitors and the thereofCYTOVIA INC·Filed 2000·Granted Jul 22, 2003·12 cites·10 claims
- 3586US6495522B1Substituted alpha-hydroxy acid caspase inhibitors and the use thereofCYTOVIA INC·Filed 2000·Granted Dec 17, 2002·31 cites·170 claims
- 3686US5559154ATri- and tetra-substituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1993·Granted Sep 24, 1996·20 cites·35 claims
- 3786US2024366513A1Methods For Administering Weight Loss MedicationsNALPROPION PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 3884US5011834APCP receptor ligands and the use thereofOREGON STATE·Filed 1989·Granted Apr 30, 1991·40 cites·26 claims
- 3984US2023301922A1Layered Pharmaceutical FormulationsNALPROPION PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 4082US6124323A4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonistsWARNER LAMBERT CO·Filed 1996·Granted Sep 26, 2000·54 cites·22 claims
- 4182US5597922AGlycine receptor antagonist pharmacophoreOREGON STATE·Filed 1994·Granted Jan 28, 1997·22 cites·6 claims
- 4281US6949516B2Dipeptide apoptosis inhibitors and the use thereofCYTOVIA INC·Filed 2003·Granted Sep 27, 2005·4 cites·14 claims
- 4381US5478863ASubstituted guanidines having high binding to the sigma receptor and the use thereofOREGON STATE·Filed 1993·Granted Dec 26, 1995·16 cites·4 claims
- 4481US2022202808A1Compositions For Affecting Weight LossNALPROPION PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 4579US5637622ATri- and tetra-substituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1995·Granted Jun 10, 1997·13 cites·24 claims
- 4679US5308869ASubstituted amidines having high binding to the sigma receptor and the use thereofOREGON STATE·Filed 1992·Granted May 3, 1994·49 cites·51 claims
- 4778US7270801B2Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereofCYTOVIA INC·Filed 2004·Granted Sep 18, 2007·3 cites·18 claims
- 4876US5767162ATri-and tetra-substituted guanidines and their use as excitatory amino acid antagonistsOREGON STATE·Filed 1995·Granted Jun 16, 1998·11 cites·27 claims
- 4976US5620978A8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptorOREGON STATE·Filed 1995·Granted Apr 15, 1997·34 cites·10 claims
- 5075US6448270B14-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonistsWARNER LAMBERT CO·Filed 2000·Granted Sep 10, 2002·6 cites·17 claims
Showing the top 50 of 109 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Eckard Weber files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →